Phase 1/2 study of oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia

Efficacy and safety of oral Decitabine/Cedazuridine (ASTX727) in the CMML subpopulation from phase 2 and ascertain phase 3 studies

Randomized phase 1-2 study to assess safety and efficacy of low-dose (LD) oral Decitabine/Cedazuridine (ASTX727) In lower-risk Myelodysplastic Syndromes (LR-MDS) patients: Interim safety analysis

Patients’ perspectives on oral Decitabine and Cedazuridine for the treatment of Myelodysplastic Syndromes

Trial in progress: A study of Tolinapant in combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine alone in participants with relapsed/refractory peripheral T-Cell Lymphoma (NCT05403450)